Rheumatoid arthritis

  title={Rheumatoid arthritis},
  author={Josef S. Smolen and Daniel Aletaha and Iain B. McInnes},
  journal={The Lancet},

Pharmacologic Management of Rheumatoid Arthritis

Treatment options for patients with rheumatoid arthritis include nonpharmacologic therapy, which includes rest, occupational and physical therapy, and weight reduction and use of assistive devices, as necessary.

Predicting and monitoring disease course in rheumatoid arthritis : imaging, biomarkers, risk factors, and integrative medicine

Findings support the value of incorporating personalized integrative medicine into clinical practice for patients with RA and suggest that allopathic practice can move towards even better proactive patient care in RA.

Diagnosis and Management of Rheumatoid Arthritis: A Review

A treat-to-target strategy aimed at reducing disease activity by at least 50% within 3 months and achieving remission or low disease activity within 6 months, with sequential drug treatment if needed, can prevent RA-related disability.

Rheumatoid arthritis

DMARDs are currently used to suppress immune abnormalities and to control disease activity and have been shown to prevent the progression of joint destruction and physical dysfunction over a long period.

Rheumatoid arthritis

The improved understanding of the pathogenetic processes involved, rational use of established drugs and development of new drugs and reliable assessment tools have drastically altered the lives of individuals with RA over the past 2 decades.

Risk Factors for Developing Rheumatoid Arthritis in Patients With Undifferentiated Arthritis and Inflammatory Arthralgia

This review aims to give an overview of clinical risk factors for developing RA, both in suspected arthralgia and in undifferentiated arthritis, taking into consideration the role of serological markers (immunological and acute phase reactants) and clinical features assessed at consultation such as: articular affection and patient's clinical perception.

An update on novel therapeutic intervention in Rheumatoid arthritis.




Rheumatoid arthritis.

Genetics and epigenetics of rheumatoid arthritis

The major advances in identifying RA genetic susceptibility markers both within and outside of the MHC are reviewed and current knowledge of the role of epigenetics in RA susceptibility is reviewed.

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

Seven new rheumatoid arthritis risk alleles were identified at genome-wide significance (P < 5 × 10−8) in an analysis of all 41,282 samples, and an additional 11 SNPs replicated at P < 0.05, suggesting that most represent genuine rhearatoid arthritisrisk alleles.

High density genetic mapping identifies new susceptibility loci for rheumatoid arthritis

This study illustrates the advantages of dense SNP mapping analysis to inform subsequent functional investigations and refined the peak of association to a single gene for 19 loci, identified secondary independent effects at 6 loci and identified association to low-frequency variants at 4 loci.

Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis

Imputation of functional variation from large reference panels can help fine map association signals in the MHC, and three amino acid positions in HLA-DRβ1, which are all located in peptide-binding grooves, almost completely explain the M HC association to rheumatoid arthritis risk.